MARKETSnap
  • Market Snapshots
    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
    • P/E Ratios
      • Large Caps
      • Absolute
      • Total Market PE
    • Stocks Performance
      • Large Caps
      • Absolute
    • Industries Performance
      • Industry
      • Sector
  • Analyze Stock
    • Analyze a stockAnalyze JNJ →
    • FindStock Picks / Stock Screener
    • Value · JNJIntrinsic Value Calculator
    • Invest · JNJInvestment Case
    • Hold · JNJ5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding
    Calculator
  • Investing Philosophy
  • More
    • Charts
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
JNJ stock logo

JNJ

Johnson & Johnson

$285.75
2.23
 (0.79%)
Exchange:  NYSE
Market Cap:  687.889B
Shares Outstanding:  2.429B
Delayed data
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  Drug Manufacturers – GeneralView industry performance
   
CEO:  Joaquin Duato
Full Time Employees:  141700
Address: 
One Johnson & Johnson Plaza
New Brunswick
NJ
8933
US
Website:  https://www.jnj.com
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Click to read more…

Revenue Segmentation

Revenue by type

Revenue by region

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Log in — it's free

JNJ full analysis

15/10/2026

Hey everyone, welcome back to MarketSnap. Johnson & Johnson just posted a beat-and-raise quarter, and the stock got hammered anyway — down almost six percent, its worst day in over a year. So here's the question that actually matters: is that drop a gift, or is the market finally waking up to something the headline numbers are hiding? We're going to strip this thing down — the revenue mix, the talc charge, the MedTech problem, and then run it through…

Listen to full analysis (audio file)

Open in MarketSnap Listen

Log in to continue

Log in to see the full analysis preview and audio links.

Log in — it's free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
JNJNJ logoJNJJohnson & Johnson687.9B43.325.715.0%
ABABBV logoABBVAbbVie Inc.521.5B50.621.116.6%
MRMRK logoMRKMerck & Co., Inc.364.3B14953.24.4%
NVNVS logoNVSNovartis AG303.1B30.818.014.0%
AZAZN logoAZNAstraZeneca PLC286.1B25.918.013.1%
AMAMGN logoAMGNAmgen Inc.251.9B26.819.815.6%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Log in — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/10/13 — Q3 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Log in — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue85,159,00088,821,00094,193,000
Gross Profit58,606,00061,350,00063,937,000
EBITDA23,320,00024,781,00041,055,000
Operating Income23,409,00022,149,00025,596,000
Net Income35,153,00014,066,00026,804,000

Log in to continue

Log in to see the income statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets167,558,000180,104,00017,500
Total Liabilities98,784,000108,614,0003,000
Total Stockholders Equity68,774,00071,490,00014,500
Total Debt29,332,00036,634,0000
Cash and Cash Equivalents21,859,00024,105,000200

Log in to continue

Log in to see the balance sheet and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow22,791,00024,266,00024,530,000
Capital Expenditure-4,543,000-4,424,000-4,832,000
Free Cash Flow18,248,00019,842,00019,698,000
Net Income13,326,00014,066,00026,804,000
Net Change in Cash7,732,0002,246,0000

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)133,703,109.767Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)137,093,836.046Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)135,218,429.911Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)52,822,637.053Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)54,326,103.259Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)53,494,529.676Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)41,743,141.223Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)43,124,036.477Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)42,360,257.411Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)33,251,218.704Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)34,094,473.444Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)33,628,070.383Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)17.440Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)17.750Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)17.180Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)17Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)1Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access to see up to 5 years of analyst estimates.

Create a free account

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
88.819B  ?P/S
 (TTM)
: 
6.92
?Net Income
 (TTM)
: 
14.066B  ?P/E
 (TTM)
: 
43.32
?Enterprise Value
 (TTM)
: 
715.63B  ?EV/FCF
 (TTM)
: 
34.76
?Dividend Yield
 (TTM)
: 
1.85%  ?Payout Ratio
 (TTM)
: 
79.01%
?ROE
 (TTM)
: 
19.56%  ?ROIC
 (TTM)
: 
15.05%
?Net Debt
 (TTM)
: 
13.312B  ?Debt/Equity
 (TTM)
: 
0.55
?P/B
 (TTM)
: 
8.58  ?Current Ratio
 (TTM)
: 
1.02

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Log in — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
25.72Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access for forward P/E high/low estimates and the full multi-year table.

Create a free account

SWOT Analysis

Strengths (preview)

  • Robust Innovative Medicine growth offsets patent cliffs: Q3 2026 revenue grew 6% year-over-year to $25.4bn, led by oncology up 17% and immunology returning to growth despite Stelara losing exclusivity. The Innovative Medicine segment generated $60.4bn in FY2025 revenue (64% of total), demonstrating scale and resilience in absorbing patent expirations.
  • Beat-and-raise quarter with upward guidance revision: JNJ beat adjusted profit estimates and raised its full-year 2026 sales and earnings outlook, citing strong pharmaceutical momentum. FY2025 net income reached $26.8bn with EPS of $11.03, and free cash flow remained robust at $19.7bn, supporting dividend commitments ($12.4bn paid in FY2025).
  • Low beta and defensive characteristics: Beta of 0.235 and dividend yield of 2.02% position JNJ as a low-volatility holding. The 1-year performance of +33.04% significantly outpaced the industry (+7.25%) and sector (+1.27%), reflecting defensive appeal amid healthcare sector weakness.

Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.

Log in to continue

Log in with Research Access for the complete SWOT analysis.

Create a free account

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates JNJ intrinsic value between $229.11 – $233.04 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate JNJ Intrinsic Value

Common questions about JNJ valuation

Is Johnson & Johnson (JNJ) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for Johnson & Johnson (JNJ) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is JNJ a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether JNJ trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is JNJ’s P/E ratio?

You can see JNJ’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for JNJ?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is JNJ a good long-term investment?

Whether JNJ fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

Research tools for Johnson & Johnson

  • Johnson & Johnson intrinsic value calculatorEstimate what the business is worth
  • Johnson & Johnson 5-year outlookWhat has to go right, and what could go wrong
JNJ

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

0.79
MarketSnap

Trading Metrics:

Open: 285   Previous Close: 283.52
Day Low: 284.03   Day High: 288.11
Year Low: 193.55   Year High: 288.11
Price Avg 50: 266.72   Price Avg 200: 249.49
Volume: 6.277M   Average Volume: 7.244M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Log in — it's free
See in Nexus

Relevant news

The Big 3: JNJ, LLY, AAPL
12-11-2026 13:00
The Big 3: JNJ, LLY, AAPL
The S&P 500 Lost 5.9% in a Month, Then Won Back More Than Half in 4 Trading Days. How Much Does a 72-Year-Old Widow Need in Dividend Stocks to Collect $5,000 a Month?
12-11-2026 09:58
The S&P 500 Lost 5.9% in a Month, Then Won Back More Than Half in 4 Trading Days. How Much Does a 72-Year-Old Widow Need in Dividend Stocks to Collect $5,000 a Month?
The Average 1-Year CD Pays Just 1.76%. These Dividend Stocks Could Pay More
06-11-2026 13:17
The Average 1-Year CD Pays Just 1.76%. These Dividend Stocks Could Pay More
4 Stocks I'm Not Selling Even If the Fed Keeps Raising Rates
06-11-2026 13:17
4 Stocks I'm Not Selling Even If the Fed Keeps Raising Rates
JNJ's Innovative Medicine Unit Grows in Q3 Despite Patent Losses
06-11-2026 13:11
JNJ's Innovative Medicine Unit Grows in Q3 Despite Patent Losses
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ
27-10-2026 18:06
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

How MarketSnap works

What’s new

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
    • Analyze a stockAnalyze JNJ →
    • FindStock Picks / Stock Screener
    • Value · JNJIntrinsic Value Calculator
    • Invest · JNJInvestment Case
    • Hold · JNJ5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding Calculator
    • Charts
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
    • Recent Activity
      • Overview
      • My Valuations
      • My Investment Journal
      • Watchlists & Portfolio
    • Settings
    • Public profile ↗
  • Log in

Media

Watch Listen Read
Ask MarketSnap AI

MarketSnap AI Assistant

Uses MarketSnap data and this page

Ready

🔒 You are currently logged out

Login

It's free

MarketSnap Assistant · Tips
    MarketSnap

    Welcome to MarketSnap

    The AI-powered workspace for stock pickers.

    Continue with Google Continue with email

    Already a member? Sign in

    Find stocks·Value them·Build the case·Journal decisions·Track what changes

    Free to join. No card needed. Privacy Policy

    Create your free MarketSnap account Continue with Google
    Chat with us MarketSnap support · account, plans, settings, help
    How MarketSnap works

    The conversation above goes to the MarketSnap team with your message. We reply by e-mail.